Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 1, 2010, Pages 49-61

  Rossini, Roberta ^a   Musumeci, Giuseppe ^a   Aprile, Alessandro ^b   Valsecchi, Orazio ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bare metal stent; Drug eluting stent; Percutaneous coronary intervention; Stent thrombosis; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLIMUS A 9; CLOPIDOGREL; EVEROLIMUS; NITRIC ACID DERIVATIVE; PACLITAXEL; POLYMER; PRASUGREL; RAPAMYCIN; RAPAMYCIN DERIVATIVE; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE HEART INFARCTION; BARE METAL STENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; STENT THROMBOSIS; TREATMENT OUTCOME; ANIMAL; COMPARATIVE STUDY; METHODOLOGY; RESTENOSIS; STENT; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950880377     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.1     Document Type: Review

References (86)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction: description of a new technique and preliminary reports of its application. Circulation 30, 654-670 (1964).
2. Hurst JW. The frst coronary angioplasty as described by Andreas Gruentzig. Am. J. Cardiol. 57, 185-186 (1986).
3. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 373, 911-918 (2009).
4. Miller JM, Ohmann EM, Moliterno DJ. Restenosis: the critical issues. In: Textbook of Interventional Cardiology (3rd Edition). Topol EJ (Ed.). Sunders, PA, USA, 379-415 (1999).
5. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, e25-e146 (2008).
6. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl. J. Med. 331(8), 496-501 (1994).
7. Butt M, Connolly D, Lip GY. Drug-eluting stents: a comprehensive appraisal. Future Cardiol. 5(2), 141-157 (2009).
8. Liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79(6), 1374-1387 (1989).
9. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105(25), 2974-2980 (2002). (Pubitemid 34693829)
10. Sousa JE, Costa MA, Sousa AG. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 107(3), 381-383 (2003).
11. Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103, 192-195 (2001).
12. Morice MC, Serruys PW, Barragan P et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: fve-year results of the RAVEL trial. J. Am. Coll. Cardiol. 50(14), 1299-1304 (2007).
13. Weisz G, Leon MB, Holmes DR Jr et al. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J. Am. Coll. Cardiol. 53(17), 1488-1497 (2009).
14. Schampaert E, Moses JW, Schofer J et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am. J. Cardiol. 98(1), 36-41 (2006).
15. Menozzi A, Solinas E, Ortolani P et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur. Heart J. 30(17), 2095-2101 (2009).
16. Kelbaek H, Kløvgaard L, Helqvist S et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J. Am. Coll. Cardiol. 51(21), 2011-2016 (2008).
17. Caixeta A, Leon MB, Lansky AJ et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol. 54(10), 894-902 (2009).
18. Waugh J, Wagstaff AJ. The paclitaxel (TAXUS)-eluting stent: a review of its use in the management of de novo coronary artery lesions. Am. J. Cardiovasc. Drugs 4(4), 257-268 (2004).
19. Grube E, Silber S, Hauptmann KE et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am. J. Cardiol. 96(1), 79-82 (2005).
20. Silber S, Colombo A, Banning AP et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. Circulation 120(15), 1498-1504 (2009).
21. Ellis SG, Stone GW, Cox DA et al. Long-term safety and effcacy with paclitaxel-eluting stents 5-year fnal results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). J. Am. Coll. Cardiol. Intv. 2, 1248-1259 (2009).
22. Grube E, Dawkins K, Guagliumi G et al. TAXUS VI fnal 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 4(5), 572-577 (2009).
23. Mehta RH, Leon MB, Sketch MH Jr. The relation between clinical features, angiographic fndings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III. Am. J. Cardiol. 100(8B), 62M-70M (2007).
24. Kirtane AJ, Gupta A, Iyengar S et al. Safety and effcacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119(25), 3198-3206 (2009).
25. Boden WE, O'Rourke RA, Teo KK et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356(15), 1503-1516 (2007).
26. Hannan EL, Wu C, Walford G et al. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. N. Engl. J. Med. 358(4), 331-341 (2008).
27. Serruys PW, Morice MC, Kappetein AP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 360(10), 961-972 (2009).
28. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667-678 (2007).
29. Rodriguez AE, Mieres J, Fernandez-Pereira C et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J. Am. Coll. Cardiol. 47, 205-207 (2006).
30. Park D-W, Park S-W, Park K-H et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98, 352-356 (2006).
31. De la Torre-Hernandez JM, Alfonso F, Hernandez F et al. Drug eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J. Am. Coll. Cardiol. 51, 986-990 (2008).
32. Kukreja N, Onuma Y, Garcia-Garcia HM et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc. Interv. 2(6), 534-541 (2009).
33. Spaulding C, Henry P, Teiger E et al Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N. Engl. J. Med. 355(11), 1093-1104 (2006).
34. Mauri L, Silbaugh TS, Wolf RE et al Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 118(18), 1817-1827 (2008).
35. Stone GW, Lansky AJ, Pocock SJ et al Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N. Engl. J. Med. 360(19), 1946-1959 (2009).
36. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N. Engl. J. Med. 349, 1315-1323 (2003).
37. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 27(23), 2784-2814 (2006).
38. Laarman GJ, Suttorp MJ, Dirksen MT et al Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N. Engl. J. Med. 355, 1105-1113 (2006).
39. Camenzind E, Steg PG, Wijns W Stent thrombosis late after implantation of frst-generation drug-eluting stents: a cause for concern. Circulation 115(11), 1440-1455 (2007).
40. Spaulding C. The question of drug-eluting stent safety: then and now. Am. J. Cardiol. 102(9 Suppl.), 12J-17J (2008).
41. Grines CL, Bonow RO, Casey DE Jr et al Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc. Interv. 69(3), 334-340 (2007).
42. Guagliumi G, Musumeci G, Rossini R et al. Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document. J. Cardiovasc. Med. 8(10), 782-791 (2007).
43. Virchow RLK. Thrombose und embolie: gefässentzündung und septische infection. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Von Meidinger & Sohn, Frankfurt am Main, Germany, 219-732 (1856).
44. Lee KW, Lip GY. Acute coronary syndromes: Virchow's triad revisited. Blood Coagul. Fibrinolysis. 14, 605-625 (2003).
45. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109, 701-705 (2004).
46. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193-202 (2006).
47. Mintz GS, Shah VM, Weissman NJ. Regional remodeling as the cause of latestent malapposition. Circulation 107, 2660-2663 (2003).
48. YC Fung. Biomechanics of the Circulation (2nd Edition). Springer-Verlag, NY, USA (1997).
49. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J. Am. Coll. Cardiol. 45, 456-459 (2005).
50. Narins CR, Zareba W, Moss AJ et al.; the Thrombogenic Factors and Recurrent Coronary Events (THROMBO) Investigators. Relationship between intermittent claudication, infammation, thrombosis and recurrent cardiac events among survivors of myocardial infarction. Arch. Intern. Med. 164, 440-446 (2004).
51. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115(11), 1433-1439 (2007).
52. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll Cardiol. 45(12), 2088-2092 (2005).
53. Pfsterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the beneft of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584-2591 (2006).
54. Stettler C, Wandel S, Allemann S et al Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937-948 (2007).
55. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356(10), 1009-1019 (2007).
56. James SK, Stenestrand U, Lindbäck J et al.; The SCAAR Study Group. Long-Term Safety and Effcacy of Drug-Eluting versus Bare-Metal Stents in Sweden. N. Engl. J. Med. 360 (19), 1933-1945 (2009).
57. Mauri L, Hsieh WH, Massaro JM, Ho KK, DAgostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N. Engl. J. Med. 356(10), 1020-1029 (2007).
58. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW A pooled analysis comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 989-997 (2007).
59. Tu JV, Bowen J, Chiu M et al. Effectiveness and safety of drug-eluting stents in Ontario. N. Engl. J. Med. 357(14), 1393-1402 (2007).
60. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 1030-1039 (2007).
61. Grines CL, Bonow RO, Casey DE Jr et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115(6), 813-818 (2007).
62. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293, 2126-2130 (2005).
63. Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116, 745-754 (2007).
64. Schulz S, Schuster T, Mehilli J et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J. 30(22), 2714-2721 (2009).
65. Kimura T, Morimoto T, Nakagawa Y et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119, 987-995 (2009).
66. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297, 159-168 (2007).
67. Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators. Optimal Timing for the Initiation of Pre-Treatment with 300 mg Clopidogrel Before Percutaneous Coronary Intervention. J. Am. Coll. Card. 47, 939-943 (2006).
68. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
69. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89, 783-787 (2003).
70. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
71. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
72. Neyt M, Van Braband Ht, Devriese S, De Laet C. Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy 91, 107-120 (2009).
73. Rastogi A, Stavchansky S. Drug eluting stent and beyond. Curr. Pharm. Des. 14, 2111-2120 (2008).
74. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52, 333-342 (2008).
75. Stone GW, Midei M, Newman W et al.; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299, 1903-1913 (2008). (Pubitemid 351574920)
76. Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 119(5), 680-686 (2009).
77. Nikolsky E, Lansky AJ, Sudhir K et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am. Heart J. 158(4), 520-526 (2009).
78. ®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2(4), 426-434 (2007).
79. Ostojic M, Sagic D, Beleslin B et al. First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes. EuroIntervention 3(5), 574-579 (2008).
80. Meredith IT, Worthley S, Whitbourn R et al.; RESOLUTE Investigators. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, frst-in-human trial. JACC Cardiovasc. Interv. 2(10), 977-985 (2009).
81. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372, 1163-1173 (2008).
82. Krucoff MW, Kereiakes DJ, Petersen JL et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. J. Am. Coll. Cardiol. 51, 1543-1552 (2008).
83. Duckers HJ, Soullié T, den Heijer P et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: fnal results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention 3(3), 350-358 (2007).
84. Beijk MA, Klomp M, Verouden NJ et al. Genous™ endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur. Heart J. DOI:10.1093/eurheartj/ehp476 (2009) (Epub ahead of print).
85. Bezerra HG, Costa MA, Guagliumi G, Rollins AM, Simon DI. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc. Interv. 2(11), 1035-1046 (2009).
86. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Cutlip DE; ENDEAVOR I Investigators. Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, frst-in-human study. Catheter Cardiovasc. Interv. 74(7), 989-995 (2009).